| 產(chǎn)品描述： | YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors |
| 靶點： |
Akt;PI3K;Angiotensin Receptor;Adrenergic Receptor;RAAS;?Akt;?PI3K;?AdrenergicReceptor |
| 體內研究： |
YS-49 (5?mg/kg; intraperitoneal injection; 8 hours; male Sprague Dawley rats) treatment significantly reduces serum NOx levels in LPS-treated rats, the NOx levels reduce from 86 μM to 34 μM |
| 參考文獻： |
1. Sun JJ, Kim HJ, Seo HG, et al. YS49,1-(alpha-naphtylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,regulates angiotensin II-stimulated ROS production, JNK phosphorylation and vascular smooth muscle cell proliferation via the induction of heme oxygen 2. Kang YJ, et al. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br J Pharmacol. 1999 Sep;128(2):357-64. 3. Hsu YH, et al. RhoA-mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27. J Cell Physiol. 2014 Oct;229(10):1455-65. |
| 溶解性： |
DMSO : 100 mg/mL (258.88 mM; Need ultrasonic) H2O : 10 mg/mL (25.89 mM; ultrasonic and warming and heat to 60°C) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.473 ml |
12.367 ml |
24.734 ml |
| 5 mM |
0.495 ml |
2.473 ml |
4.947 ml |
| 10 mM |
0.247 ml |
1.237 ml |
2.473 ml |
| 50 mM |
0.049 ml |
0.247 ml |
0.495 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京